Business
Ultragenyx Stock Halves After Its Angelman Syndrome Drug Fails a Pivotal Trial
GTX-102 missed all its goals in a Phase 3 study for the rare disorder, wiping out a would-be blockbuster and pushing the company toward significant cost cuts.